Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma-MedSci.cn

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

Song, YQ; Zhou, KS; Yang, SM; Hu, JD; Zou, DH; Gao, SJ; Pan, L; Wang, TY; Yang, HY; Zhang, HL; Zhou, DB; Ji, J; Xu, W; Feng, R; Jin, J; Lv, FF; Huang, HW; Fan, XS; Xu, S; Zhu, J

Song, YQ; Zhu, J (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Lymphoma, Beijing Canc Hosp, 52 Fucheng Rd, Beijing 100142, Peoples R China.

Abstract

We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

科室

工具

服务